La relación de médicos participantes en el Documento de Consenso se incluye al final del artículo.
Journal Information
Vol. 35. Issue 7.
Pages 339-344 (July - August 1999)
Vol. 35. Issue 7.
Pages 339-344 (July - August 1999)
Full text access
Consenso sobre determinados aspectos de la patología pulmonar en pacientes con fibrosis quística
Visits
4091
L. Maiza,
, C. Antelob, F. Baqueroc, N. Cobosd, P. Moralese, J. Pérez-Fríasf, C. Vázquezg
Corresponding author
luis.maiz@hrc.es
Correspondencia: Unidad de Fibrosis Quística. Servicio de Neumología. Hospital Ramón y Cajal. Ctra. Colmenar, km. 9.1.28034 Madrid.
Correspondencia: Unidad de Fibrosis Quística. Servicio de Neumología. Hospital Ramón y Cajal. Ctra. Colmenar, km. 9.1.28034 Madrid.
a Servicio de Neumología. Hospital Ramón y Cajal. Madrid
b Servicio de Pediatría. Hospital La Paz. Madrid
c Servicio de Microbiología. Hospital Ramón y Cajal. Madrid
d Servicio de Pediatría. Hospital Vall d’Hebron. Barcelona
e Servicio de Neumología. Hospital La Fe. Valencia
f Servicio de Pediatría. Hospital Carlos Haya. Málaga
g Servicio de Pediatría. Hospital de Cruces. Vizcaya
This item has received
Article information
Full text is only aviable in PDF
Bibliografía
[1.]
B.J. Rosenstein, G.R. Cutting, for the Cystic Fibrosis Foundation Consensus Panel.
The diagnosis of cystic fibrosis: a consensus statement.
J Pediatr, 132 (1998), pp. 389-595
[2.]
Cystic Fibrosis Foundation.
Patient Registry 1994 Animal Data Report.
The Foundation, (1995),
[4.]
J.J. Hagan, A.A. Woodcock.
Management of cystic fibrosis before and after lung transplantation.
J Roy Soc Med, 90 (1997), pp. 47-58
[5.]
J.R. Yankaskas, G.B. Mallory, the Consensus Committe.
Lung transplantation in cystic fibrosis consensus confcrence statement.
Chest, 113 (1998), pp. 217-226
[6.]
S. Lanng, A. Hansen, B. Thorsteinsson, J. Nerup, C. Koch.
Glucose tolerance in patients with cystic fibrosis: five year prospective study.
BMJ, 311 (1995), pp. 655-659
[7.]
J.R.W. Govan, J.W. Nelson.
Microbiology of lung infections in cystic fibrosis.
Br Med Bull, 48 (1992), pp. 912-930
[8.]
B.W. Ramsey, K.R. Wentz, A.L. Smith, M. Richardson, J. Williams-Warren, D.L. Hedges, et al.
Predictive valúe of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients.
Am Rev Respir Dis, 144 (1991), pp. 331-337
[9.]
C.J. Hodson, E.N. France.
Pulmonary changes in cystic fibrosis of the pancreas, a radio-pathological study.
Clin Radiol, 13 (1962), pp. 54-61
[10.]
G.J. Redding, R. Restuccia, E.K. Cotton, J.G. Brooks.
Serial changes in pulmonary function in children hospitalised for cystic fibrosis.
Am Rev Respir Dis, 126 (1982), pp. 31-36
[11.]
E. Kerem, J. Reisman, M. Corey, M. Corey, G.J. Canny, H. Levison.
Prediction of mortality in patients with cystic fibrosis.
N Engl J Med, 326 (1992), pp. 1.187-1.191
[12.]
S.B. Fiel.
Clinical management of pulmonary disease in cystic fibrosis.
Lancet, 341 (1993), pp. 1.070-1.074
[13.]
A.L. Smith, G. Reddding, Doershuk, D. Goldmann, E. Gore, B. Hilman, et al.
Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis.
J Pediatr, 112 (1988), pp. 547-554
[14.]
B.W. Ramsey.
Management of pulmonary disease in patients with cystic fibrosis.
N Engl J Med, 335 (1996), pp. 179-187
[15.]
S.V. Turpin, M.R. Knowles.
Treatment of pulmonary disease in patients with cystic fibrosis.
Cystic fibrosis, pp. 277-344
[16.]
P.B. Davis, M. Drumm, M.W. Konstan.
Cystic fibrosis.
State of the art. Am J Respir Crit Care Med, 154 (1996), pp. 1.229-1.256
[17.]
T.T. Rubio.
Ciprofloxac: comparative data in cystic fibrosis.
Am J. Med, 82 (1987), pp. 185-188
[18.]
M.E. Hodson, C.M. Roberts, R.J.A. Burtland, M.J. Smith, C. Batten.
Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis.
Lancet, 1 (1987), pp. 235-237
[19.]
G. Radberg, L.E. Nilsson, S. Svensson.
Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin.
Antimicrob Agents Chemother, 34 (1990), pp. 2.142-2.147
[20.]
D.J. Touw, R.W. Brimicombe, M.E. Hodson, H.G.M. Heijerman, W. Bakker.
Inhalation of antibiotics in cystic fibrosis.
Eur Respir J, 8 (1995), pp. 1.549-1.604
[21.]
S. Mukdhopadhyay, M. Singh, J.I. Cater, S. Ogston, M. Franklin, R.E. Olver.
Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks.
Thorax, 51 (1996), pp. 361-368
[22.]
V. Bhargava, J.F. Tomashefski Jr., R.C. Stern, C.R. Abrantowsky.
The pathology of fungal infection and colonization in patients with cystic fibrosis.
Hum Pathol, 20 (1989), pp. 911-986
[23.]
M.E. Hodson.
Respiratory system: Adults.
Cystic Fibrosis, pp. 237-257
[24.]
B.W. Ramsey, S.J. Astley, M.L. Aitken, W. Burke, A.A. Colin, H.L. Dorkin, et al.
Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.
Am Rev Respir Dis, 148 (1993), pp. 145-151
[25.]
H.J. Fuchs, D.S. Borowitz, D.H. Christiansen, E.M. Morris, M.L. Nash, B.W. Ramsey, et al.
Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis.
N Engl J Med, 331 (1994), pp. 637-642
Copyright © 1999. Sociedad Española de Neumología y Cirugía Torácica